Suppr超能文献

抗精神病药物与精神分裂症患者代谢紊乱风险:一项使用英国临床实践研究数据库的纵向研究。

Antipsychotic Medication and Risk of Metabolic Disorders in People With Schizophrenia: A Longitudinal Study Using the UK Clinical Practice Research Datalink.

机构信息

The National Institute for Health Research Applied Research Collaboration West (NIHR ARC West) at University Hospitals Bristol and Weston NHS Foundation Trust, Bristol, UK.

Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.

出版信息

Schizophr Bull. 2024 Mar 7;50(2):447-459. doi: 10.1093/schbul/sbad126.

Abstract

BACKGROUND AND HYPOTHESIS

Antipsychotics are first-line drug treatments for schizophrenia. When antipsychotic monotherapy is ineffective, combining two antipsychotic drugs is common although treatment guidelines warn of possible increases in side effects. Risks of metabolic side effects with antipsychotic polypharmacy have not been fully investigated. This study examined associations between antipsychotic polypharmacy and risk of developing diabetes, hypertension, or hyperlipidemia in adults with schizophrenia, and impact of co-prescription of first- and second-generation antipsychotics.

STUDY DESIGN

A population-based prospective cohort study was conducted in the United Kingdom using linked primary care, secondary care, mental health, and social deprivation datasets. Cox proportional hazards models with stabilizing weights were used to estimate risk of metabolic disorders among adults with schizophrenia, comparing patients on antipsychotic monotherapy vs polypharmacy, adjusting for demographic and clinical characteristics, and antipsychotic dose.

STUDY RESULTS

Median follow-up time across the three cohorts was approximately 14 months. 6.6% developed hypertension in the cohort assembled for this outcome, with polypharmacy conferring an increased risk compared to monotherapy, (adjusted Hazard Ratio = 3.16; P = .021). Patients exposed to exclusive first-generation antipsychotic polypharmacy had greater risk of hypertension compared to those exposed to combined first- and second-generation polypharmacy (adjusted HR 0.29, P = .039). No associations between polypharmacy and risk of diabetes or hyperlipidemia were found.

CONCLUSIONS

Antipsychotic polypharmacy, particularly polypharmacy solely comprised of first-generation antipsychotics, increased the risk of hypertension. Future research employing larger samples, follow-up longer than the current median of 14 months, and more complex methodologies may further elucidate the association reported in this study.

摘要

背景和假设

抗精神病药是精神分裂症的一线药物治疗方法。当抗精神病药单药治疗无效时,联合使用两种抗精神病药很常见,尽管治疗指南警告可能会增加副作用。抗精神病药联合用药的代谢副作用风险尚未得到充分研究。本研究检查了抗精神病药联合用药与精神分裂症成人发生糖尿病、高血压或血脂异常的风险之间的关联,以及第一代和第二代抗精神病药联合用药的影响。

研究设计

本研究采用英国基于人群的前瞻性队列研究,使用了初级保健、二级保健、心理健康和社会剥夺数据集进行关联。使用稳定权重的 Cox 比例风险模型来估计精神分裂症成人代谢紊乱的风险,比较抗精神病药单药治疗与联合用药的患者,调整人口统计学和临床特征以及抗精神病药剂量。

研究结果

三个队列的中位随访时间约为 14 个月。该结果队列中 6.6%的人患有高血压,与单药治疗相比,联合用药增加了患病风险(调整后的危害比=3.16;P=0.021)。与联合使用第一代和第二代抗精神病药相比,仅暴露于第一代抗精神病药联合用药的患者高血压风险更高(调整后的 HR 0.29,P=0.039)。未发现联合用药与糖尿病或血脂异常风险之间存在关联。

结论

抗精神病药联合用药,特别是仅由第一代抗精神病药组成的联合用药,增加了高血压的风险。未来的研究采用更大的样本量、比当前中位数 14 个月更长的随访时间和更复杂的方法学,可能会进一步阐明本研究报告的关联。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/a547/10919771/1106ec701615/sbad126_fig1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验